Swiss drugmaker Novartis AG said Monday that its meningitis vaccine Menveo has been approved for use in teenagers and adults by the U.S. Food and Drug Administration.
Menveo is a vaccine against four common types of bacterial meningitis, which affects between 1,000 and 3,000 people each year in the United States.
The U.S. regulator approved the drug for people between 11 and 55, Novartis said.
[ABC News]